Evidence map›Paper›PMID 33333825›Full record

ArticleInternational journal of molecular sciences2020

Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.

Jay Perry, Bruce Ashford, Amarinder Singh Thind, Marie-Emilie Gauthier, Elahe Minaei, Gretel Major, Narayanan Gopalakrishna Iyer, Ruta Gupta, Jonathan Clark, Marie Ranson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Jay PerryMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0003-1153-4609
Bruce AshfordMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Amarinder Singh ThindIllawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia.ORCID 0000-0003-4592-0380
Marie-Emilie GauthierKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Elahe MinaeiMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Gretel MajorMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0002-4275-4199
Narayanan Gopalakrishna IyerDepartment of Surgical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.
Ruta GuptaSydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia.
Jonathan ClarkSydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia.
Marie RansonMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0002-5570-9645
Translational Research Institute · AUUniversity of Wollongong · AUChris O’Brien Lifehouse · AUGarvan Institute of Medical Research · AUNational Cancer Centre Singapore · SGRoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer. Most patients who develop metastases (2-5%) present with advanced disease that requires a combination of radical surgery and adjuvant radiation therapy. There are few effective therapies for refractory disease. In this study, we describe novel patient-derived cell lines from cSCC metastases of the head and neck (designated UW-CSCC1 and UW-CSCC2). The cell lines genotypically and phenotypically resembled the original patient tumor and were tumorogenic in mice. Differences in cancer-related gene expression between the tumor and cell lines after various culturing conditions could be largely reversed by xenografting and reculturing. The novel drug susceptibilities of UW-CSCC1 and an irradiated subclone UW-CSCC1-R to drugs targeting cell cycle, PI3K/AKT/mTOR, and DNA damage pathways were observed using high-throughput anti-cancer and kinase-inhibitor compound libraries, which correlate with either copy number variations, targetable mutations and/or the upregulation of gene expression. A secondary screen of top hits in all three cell lines including

Indexed as

AgedAged, 80 and overAnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorComputational BiologyDNA Copy Number VariationsGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50MaleMiceMice, Inbred NODPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsAntineoplastic AgentsMTOR protein, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSmall Molecule LibrariesTOR Serine-Threonine Kinasescancercell culturecSCCgene expressionmetastasisPI3Kskin cancerultravioletWGSxenograft

Identifiers

PMID33333825
PMCPMC7765308
OpenAlexW3111268950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.